ANL

Adlai Nortye Ltd. (NASDAQ:ANL) is a clinical-stage biotechnology company founded in 2018 and incorporated in the Cayman Islands. The company went public in September 2023 and focuses on discovering and developing innovative cancer therapies for patients in the United States and Mainland China. As a relatively young biotech firm, Adlai Nortye is currently in the clinical development phase with its lead drug candidate progressing through Phase III trials, while maintaining a robust pipeline of preclinical and early-stage therapeutic programs targeting various cancer pathways.